A SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma

Abstract Background PD-L1 immunotherapy plays a crucial role in cancer treatment, but PD-L1 peptide vaccines have low immunogenicity. A potent peptide derived from the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a significant adjuvant effect, which may increase...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Chia-Hung Chen, Tzu-Han Weng, Ta-Wei Kuo, Kai-Yao Huang, Yu-Chi Chen, Hsiao-Hsuan Huang, Hui-Ju Kao, Chen-Lin Yu, Chen-Chen Huang, Shun-Long Weng, Kuang-Wen Liao
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMC 2025-12-01
Saila:	Molecular Medicine
Gaiak:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PD-L1 Bioinformatics analysis Melanoma
Sarrera elektronikoa:	https://doi.org/10.1186/s10020-025-01384-2
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!